02168nas a2200361 4500000000100000008004100001260005300042653002400095653002700119653001700146653002400163653001500187100001800202700001300220700002000233700001400253700001600267700002600283700002000309700001300329700001900342700002600361700001500387700002200402700001300424700002000437245009300457856006000550300001400610490000700624520115000631022002501781 2020 d bCenters for Disease Control and Prevention (CDC)10aInfectious Diseases10aMicrobiology (medical)10aEpidemiology10aChromoblastomycosis10aMadagascar1 aRasamoelina T1 aMaubon D1 aAndrianarison M1 aRanaivo I1 aSendrasoa F1 aRakotozandrindrainy N1 aRakotomalala FA1 aBailly S1 aRakotonirina B1 aAndriantsimahavandy A1 aRabenja FR1 aAndrianarivelo MR1 aCornet M1 aRamarozatovo LS00aEndemic Chromoblastomycosis Caused Predominantly by Fonsecaea nubica, Madagascar1 uhttps://wwwnc.cdc.gov/eid/article/26/6/pdfs/19-1498.pdf a1201-12110 v263 a

Chromoblastomycosis is an implantation fungal infection. Twenty years ago, Madagascar was recognized as the leading focus of this disease. We recruited patients in Madagascar who had chronic subcutaneous lesions suggestive of dermatomycosis during March 2013–June 2017. Chromoblastomycosis was diagnosed in 50 (33.8%) of 148 patients. The highest prevalence was in northeastern (1.47 cases/100,000 persons) and southern (0.8 cases/100,000 persons) Madagascar. Patients with chromoblastomycosis were older (47.9 years) than those without (37.5 years) (p = 0.0005). Chromoblastomycosis was 3 times more likely to consist of leg lesions (p = 0.003). Molecular analysis identified Fonsecaea nubica in 23 cases and Cladophialophora carrionii in 7 cases. Of 27 patients who underwent follow-up testing, none were completely cured. We highlight the persistence of a high level of chromoblastomycosis endemicity, which was even greater at some locations than 20 years ago. We used molecular tools to identify the Fonsecaea sp. strains isolated from patients as F. nubica.

 a1080-6040, 1080-6059